The potential of proteogenomics in oncology

Great improvements have been achieved during the last 5 years on the detection of somatic mutations and this mainly thanks to the introduction of massive parallel sequencing technologies (NGS). The development of high-throughput methods allows a deeper, easier and faster analysis of the mutational status of tumors and, with no doubts, is going to lead to a new classification of the oncologic diseases that will parallel and permeate the standard anatomo-histological criteria.